KRP-203 clinical trials
How each study uses KRP-203 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the KRP-203 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
4 studies that test it; most in 2010 (1)
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2011 | 1 |
| 2013 | 1 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Novartis Pharmaceuticals (3) · Priothera SAS (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1, 1 in phase 3
Studies that test KRP-203, phase 3 first.
- May 2027Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCTPhase 3 · Priothera SAS
Studies
Open first, then newest update. How each study uses KRP-203 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCTRecruitingPhase 3Priothera SASNCT05429632Written as mocravimod
- A Two-part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of KRP203 in Patients Undergoing Stem Cell Transplant for Hematological MalignanciesCompletedPhase 1Novartis PharmaceuticalsNCT01830010Written as Study Part 1: KRP203
- Efficacy & Safety in Moderately Active Refractory Ulcerative Colitis PatientsTerminatedPhase 2Novartis PharmaceuticalsNCT01375179Written as KRP203
- Safety and Efficacy of KRP203 in Subacute Cutaneous Lupus ErythematosusCompletedPhase 2Novartis PharmaceuticalsNCT01294774Written as KRP203 - 1.2mg
Codes
What other systems call KRP-203 · ClinicalTrials.gg INT004793
- UNII (FDA) X71GCJ0HLIMOCRAVIMODConfirmed FDA, Wikidata
- Wikidata Q27293620krp-203 free baseConfirmed FDA, Wikidata
- DrugBank DB18151One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | X71GCJ0HLI | MOCRAVIMOD | Confirmed FDA, Wikidata |
| Wikidata | Q27293620 | krp-203 free base | Confirmed FDA, Wikidata |
| DrugBank | DB18151 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.